If you're looking to add some growth to your portfolio, a great way to do it is by picking up shares of a biotech company with a recently approved product. Such a treatment will represent a brand new revenue driver for the company -- and sometimes, even its first one -- so if the product takes off, the share price may follow. In many cases, this marks the very start of the biotech's growth story, allowing you to get in early and benefit over time.

This is the case for Iovance Biotherapeutics (NASDAQ: IOVA) and CRISPR Therapeutics (NASDAQ: CRSP) today. Each of these biotech players recently won approval for its first product -- and these aren't only regulatory victories, but also votes of confidence in the game-changing technologies they have developed. These stocks both represent interesting growth opportunities today. But if you could only choose one to add to your portfolio, which would be the better buy?

Image source: Getty Images.

Continue reading

Source Fool.com